Sage Therapeutics Inc.’s stock slid 4.7% Thursday, after the biotech said it’s cutting about 33% of its workforce as part of an overhaul of its business and pipeline that’s expected to ...

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) have been given a consensus rating of “Hold” by the ...

Sage Therapeutics, Inc. SAGE reported a loss of $1.56 per share for the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.45. The company had reported a loss of 55 ...

Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the stock’s rating to Underperform, noting that the impact of Biogen’s ...

Fast Company recognized Sage Therapeutics as one of the most innovative medicines and therapeutics companies for its pill for postpartum depression. This company created the first-ever FDA ...

NEW YORK, NY / ACCESS Newswire / March 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

U.S. stock futures were swinging between gains and losses on Thursday after snapping a three-day winning streak on Wednesday. Futures of major benchmark indices were mixed in premarket trading.

US Bancorp DE raised its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) by 22.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC.